Chimeric antigen receptor(CAR) T-cell therapy is effective in relapsed/refractory large B-cell lymphoma(LBCL), but evidence in elderly patients(≥70y) is limited. We compared outcomes of tisagenlecleucel(tisa-cel) and axicabtagene ciloleucel(axi-cel) and assessed prognostic factors. We analyzed 1,191 patients(aged ≥70y) reported to the EBMT(tisa-cel n=402; axi-cel n=789). Median follow-up was 22.7 months. Outcomes included cytokine release syndrome(CRS), immune effector cell-associated neurotoxicity syndrome(ICANS), overall survival(OS), progression-free survival(PFS), relapse incidence(RI), and non-relapse mortality(NRM). Multivariable models adjusted for age, sex, ECOG, disease status, prior transplantation, and year of infusion. Median age at infusion was 74y; 65.6% were aged 70-75y. Progressive disease at infusion was 59% vs 53% for tisa-cel and axi-cel(p=0.04). Tisa-cel patients were older(74.0 vs 73.7y, p=0.019). At day-30, CRS(any grade) occurred in 62% vs 77%(p.
Vanderson Rocha, J. Mooyaart, R. Ram et al.· Haematologica· 0 citations
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for high-risk acute myeloid leukemia (AML), and outcomes are strongly influenced by disease status at transplantation. In transplants using conventional graft-versus-host disease (GVHD) prophylaxis, outcomes also depend on the number of induction courses required to achieve first complete remission (CR1); however, this has not been evaluated in patients receiving post-transplant cyclophosphamide (PTCy). We retrospectively analyzed 677 adult AML patients transplanted in CR1 between 2012 and 2022 using PTCy-based GVHD prophylaxis. Outcomes were compared between patients achieving CR1 after one induction course (n = 518) and those requiring two courses (n = 159). Baseline characteristics, donor type, conditioning intensity, graft source, engraftment, and rates of acute and chronic GVHD were comparable between groups. Patients requiring two inductions had a higher 2-year cumulative incidence of relapse (27% vs. 19.3%; HR 1.75, p = 0.003). However, no significant differences were observed in 2-year overall survival (62.8% vs. 69%), leukemia-free survival (61.1% vs. 65%), GVHD-free/relapse-free survival (46.3% vs. 50.4%), or non-relapse mortality (11.9% vs. 15.7%). In AML patients receiving alloHSCT with PTCy, outcomes were largely similar regardless of whether CR1 was achieved after one or two-induction courses, with relapse incidence being higher in patients requiring 2 inductions.
A. Nagler, R. Swoboda, Allain-Thibeault Ferhat et al.· Bone Marrow Transplantation· 0 citations
Cellular therapies, namely autologous hematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) and more recently, chimeric antigen receptor T-cell therapies (CART), play a major role in state-of-the-art treatment of mantle cell lymphoma (MCL). With numerous therapeutic innovations currently entering the MCL treatment landscape, guidance for indication, sequencing and application of cellular therapies is of key importance. To address this practical need, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonisation and Guidelines Committee convened an international expert meeting in Berlin on Sept 29/30, 2025. EBMT provided funding and logistical support. Two appointed chairpersons invited experts in MCL and cellular therapy, who completed three work packages devoted to the three types of cellular therapy. A literature search was performed beforehand and suitable published evidence was considered collectively in structured discussions and consensus-building exercises. The recommendations developed as a result of this process provide a sound basis for practical counseling and decision-making in the care of patients with treatment-naïve and relapsed/refractory MCL.
P. Dreger, G. Iacoboni, S. Robinson et al.· Bone Marrow Transplantation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
